Rituxan lupus is becoming an option for the treatment of the disease for several reasons. One of the reasons is that increased or abnormal B-cell activity is a factor in lupus and other autoimmune diseases and can be treated with drugs such as rituxan. Indeed, rituxan has the ability to decrease the number of B defective B cells attacked by lupus related symptoms.

The rituxan mode of action against B cells includes attacking the B cells that are still in transition phase, or in an adolescent phase. These cells are unable to participate in the immune system response to intruders thus the attack by the drug.   Doctors have noticed that patients who took rituxan improved and had more healthy B cells.

Meanwhile, these patients have few mature cells thus their immune system is unable to mount a responsive attack against bacteria and viruses. It thus becomes important to monitor this group of patients closely for risks of infections.

On the other hand, the fact that lupus patients who were disease-free for years had a B-cell profile that resembled those following B-cell depletion suggests that there may be ways to change the makeup of the immune system cells that may also fundamentally alter the autoimmune disease process. That could potentially lead to longer-term benefits.

 

Lupus Rituxan Work Mechanism

 

The combination of rituxan and lupus treating drugs has been an approved treatment option. This combination revolves around the use of antibodies that act on B cells that are in their early stages.

The effect of the combination of rituxan and lupus result in the elimination of cancerous B cells from the body. This elimination allows a new population of healthy B cells to develop from lymphoid stem cells.